Navigation Links
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

e(R) (VNP40101M) treatment arm versus 9% for the control arm. Sepsis, pneumonia and infection accounted for 67% of the deaths on the treatment arm.

The most common severe adverse events (Grade 3 through 5) in both arms were hematologic, infectious, and respiratory disorders. The duration of myelosuppression, as well as the incidence of infectious and respiratory adverse events, was higher in the treatment arm as compared to the control arm.

Alan Kessman, Chief Executive Officer, said, "Although this trial was discontinued for safety reasons due to a disparity in on-study mortality between the two arms, in light of the objective response rate of the cytarabine and Cloretazine(R) (VNP40101M) arm, we believe that this combination merits further evaluation in first relapse of AML with modifications to address the observed toxicity and mortality at the studied dose and schedule."

At ASCO(R), data were presented on the first 206 patients treated on the trial. The median age was 59 years and the median duration of patients' first remission was 9.7 months. 139 patients and 67 patients were treated on the treatment arm and the control arm respectively. The demographics of the patients in the treatment arm were essentially similar to patients in the control arm across age, sex, and ECOG performance status.

Mr. Kessman added, "Now that the clinical hold has been lifted by the FDA, we have the opportunity to move forward in first relapse of AML with a revised protocol of this combination. However, our main focus at the present time continues to be on achieving registration for Cloretazine(R) (VNP40101M) in the United States in previously untreated elderly patients with de novo poor-risk AML."

The Phase III trial was a double-blind placebo-controlled randomized evaluation of a treatment arm consisting of cytarabine plus Cloretazine(R) (VNP40101M) versus a control arm regimen of cytarabine and placebo. The trial was designed to accrue patients i
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
(Date:12/25/2014)... LunaDress.co.uk has updated its blog to provide professional shopping tips on ... models at LunaDress.co.uk come with big discounts, up to 80 percent ... turn out to be a most exciting memory and can show ... surprise to a wedding. On the updated fashion blog, ladies can ... a big day . , Going out with friends to a ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... networks , , FRIDAY, April 24 (HealthDay News) -- Better ... has led to steady improvements in the time needed ... heart attack, new research shows. , The study involved ... myocardial infarction (STEMI), the deadliest type of heart attack. ...
... researchers report , , FRIDAY, April 24 (HealthDay News) -- ... after heart bypass surgery are at increased long-term risk ... sounds a warning bell for doctors about an issue ... said Giovanni Filardo, director of the department of epidemiology ...
... advantage, study finds, , , FRIDAY, April 24 (HealthDay News) -- ... in better health than the general population, but for veterans ... , In fact, aging combat veterans have a poorer quality ... that was to be presented Friday at the American Heart ...
... New policy papers addressing comprehensive payment reform and ... released today by the American College of Physicians ... , Reforming Physician Payments to Achieve Greater ... Challenges Facing Primary Care Medicine: Comprehensive Strategies from ...
... Talecris Biotherapeutics, Inc. today announced the publication ... the largest clinical trial ever conducted in patients ... April 14, 2009 issue of Neurology . ... Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) ...
... Drug Companies to Adopt "Smart" Drug Safety TechnologyARMONK, N.Y. ... -- IBM (NYSE: IBM ... Golden State Medical Supply (GSMS) today announced the two ... with stringent prescription drug pedigree regulations in advance of ...
Cached Medicine News:Health News:Coordination Has Led to Quicker Heart Treatment 2Health News:Abnormal Heartbeat After Bypass a Bad Sign 2Health News:Combat Duty Harms Long-Term Health of Vets 2Health News:Combat Duty Harms Long-Term Health of Vets 3Health News:Payment reform and solutions to challenges facing primary care addressed in policy papers 2Health News:Payment reform and solutions to challenges facing primary care addressed in policy papers 3Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 2Health News:Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP 3Health News:IBM and Golden State Medical Supply Create Drug Safety Model to Help Combat Counterfeiting 2Health News:IBM and Golden State Medical Supply Create Drug Safety Model to Help Combat Counterfeiting 3
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, ... and partner Auxilium Pharmaceuticals, Inc. today announced that the ... the European Medicines Agency (EMA) has adopted a positive ... for the treatment of adult men with Peyronie,s disease ... least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... PLC Systems Inc. (OTCBB: PLCSF), a company focused ... has named Susan Papalia, RN, BSN, Vice President of ... responsible for overseeing and leading the U.S. clinical study ... obtained the CE Mark in the European Union, and ...
... Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and ... in Paris.  Dr. Fernandes will present at the 18th ... at the Hilton Arc de Triomphe.  Dr. Fernandes will later ... CET, May 24, at the Paris Marriott Rive Gauche.  Dr. ...
Cached Medicine Technology:PLC Medical Systems Adds Vice President of Clinical Affairs 2PLC Medical Systems Adds Vice President of Clinical Affairs 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
Auto refractometer....
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... The Selecta II Glaucoma Laser System features ... patients with open-angle glaucoma. It selectively targets ... intraocular pressure. The Selecta II is equipped ... high-energy beam of light, which induces the ...
Round handle....
Medicine Products: